Gross Profit Trends Compared: Gilead Sciences, Inc. vs Perrigo Company plc

Pharma Giants' Profit Trends: Gilead vs. Perrigo

__timestampGilead Sciences, Inc.Perrigo Company plc
Wednesday, January 1, 2014211020000001447700000
Thursday, January 1, 2015286330000001712400000
Friday, January 1, 2016261290000002051800000
Sunday, January 1, 2017217360000001979500000
Monday, January 1, 2018172740000001831500000
Tuesday, January 1, 2019177740000001773300000
Wednesday, January 1, 2020201170000001815200000
Friday, January 1, 2021207040000001416200000
Saturday, January 1, 2022216240000001455400000
Sunday, January 1, 2023206180000001680400000
Monday, January 1, 202478200000
Loading chart...

Data in motion

Gross Profit Trends: Gilead Sciences vs. Perrigo Company

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Gilead Sciences, Inc. and Perrigo Company plc have showcased distinct trajectories in their gross profits. From 2014 to 2023, Gilead Sciences experienced a peak in 2015 with a gross profit of approximately $28.6 billion, marking a 36% increase from the previous year. However, by 2018, their profits dipped to around $17.3 billion, a 40% decline from the peak. In contrast, Perrigo Company maintained a more stable growth, peaking in 2016 with a gross profit of about $2.05 billion, a 42% increase from 2014. Despite fluctuations, both companies have shown resilience, with Gilead's profits rebounding to over $20 billion by 2023. This analysis highlights the dynamic nature of the pharmaceutical sector and the importance of strategic financial planning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025